Synthesis of doxorubicin containing drug carriers and their in-vitro performance on HeLa and HCT116 cells

To further the options available for a more efficient anticancer therapy, we modified lipid carriers of the anticancer agent doxorubicin (Dox). In utilizing a previously reported differential sensitivity of HeLa and HCT116 cells to 1mM Dox, our results show a more than 50% decreased survival rate of the more resistant HeLa cells to 1mM Dox, delivered via our new carrier system; the blank carrier system does not impair the survival rate of the more sensitive HCT116 cells. This internally validated assay may be regarded as advantageous in determining the efficacy of drug delivery systems.